Get the Stockscreener App
3.43
7.81%
0.23
After Hours:
3.32
-0.11
-3.21%
Agenus Inc stock is traded at $3.43, with a volume of 899.93K.
It is up +7.81% in the last 24 hours and up +19.38% over the past month.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$3.20
Open:
$3.19
24h Volume:
899.93K
Relative Volume:
1.34
Market Cap:
$94.05M
Revenue:
$160.43M
Net Income/Loss:
$-227.64M
P/E Ratio:
-0.0499
EPS:
-68.77
Net Cash Flow:
$-170.79M
1W Performance:
-9.69%
1M Performance:
+19.38%
6M Performance:
+0.88%
1Y Performance:
-77.17%
1-Day Range:
$3.00
$3.4999
1-Week Range:
$2.95
$3.895
52-Week Range:
$1.38
$19.69
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.43 | 103.91M | 160.43M | -227.64M | -170.79M | -68.77 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Agenus presents new translational data at 2025 ASCO meeting - TipRanks
Agenus (AGEN) Reports Promising Data on Botensilimab Therapy | AGEN Stock News - GuruFocus
Agenus Presents New Data at ASCO Highlighting Botensilimab's Imm - GuruFocus
Cancer Breakthrough: How Botensilimab Activates Immune Response in 'Untreatable' Colorectal CancerASCO Data - Stock Titan
Agenus (NASDAQ:AGEN) Share Price Passes Above 200-Day Moving Average – Should You Sell? - Defense World
Peptide Cancer Vaccine Market Detailed In New Research Report - openPR.com
Agenus (NASDAQ:AGEN) Raised to Hold at Wall Street Zen - Defense World
Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide (AGEN) - Seeking Alpha
Agenus Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationAGEN - ACCESS Newswire
Agenus Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationAGEN - ACCESS Newswire
What is B. Riley’s Estimate for Agenus FY2025 Earnings? - Defense World
Richard Goldberg joins Agenus as chief development officer - The Cancer Letter
Agenus says expanded MSS mCRC cohort data to be presented at ESMO GI - Yahoo Finance
HC Wainwright Weighs in on Agenus’ Q2 Earnings (NASDAQ:AGEN) - Defense World
Agenus (AGEN) Reveals Insights from Phase 1 Trial on Cancer Trea - GuruFocus
Agenus Announces New Data from Expanded MSS Metastatic Colorecta - GuruFocus
Agenus (AGEN) Reveals Insights from Phase 1 Trial on Cancer Treatment | AGEN Stock News - GuruFocus
Major Clinical Trial Update: Agenus Reveals New Colorectal Cancer Data From 123-Patient Study at ESMO - Stock Titan
Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025 - The Joplin Globe
Agenus Inc. (NASDAQ:AGEN) Shares Acquired by Barclays PLC - Defense World
Agenus Inc. (NASDAQ:AGEN) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Robert W. Baird Forecasts Strong Price Appreciation for Agenus (NASDAQ:AGEN) Stock - Defense World
Peptide Cancer Vaccine Market Set to Witness Significant Growth - openPR.com
Wells Fargo & Company MN Decreases Holdings in Agenus Inc. (NASDAQ:AGEN) - Defense World
Agenus (AGEN) Target Price Raised by Analyst Baird | AGEN Stock News - GuruFocus
Agenus (AGEN) Registers Plan to Offer 165,000 Common Shares | AGEN Stock News - GuruFocus
Analyst Reiterates Neutral Rating for Agenus (AGEN) | AGEN Stock News - GuruFocus
Agenus (AGEN) Receives Price Target Increase from Baird | AGEN S - GuruFocus
Agenus Inc. (NASDAQ:AGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
Agenus names Dr Richard Goldberg as CDO - Medical Buyer
Agenus (AGEN) Moves to Sell 165,000 Shares of Common Stock - GuruFocus
Agenus Inc (AGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges - Yahoo Finance
Agenus Inc (AGEN) Q1 2025 Earnings Call Highlights: Strategic Mo - GuruFocus
Agenus Inc. Reports Q1 2025 Progress and Financials - TipRanks
Agenus Inc. Earnings Call: Optimism Amid Challenges - TipRanks
Agenus signals near-term strategic transactions and operational cash burn target below $50M amid BOT/BAL data advances - MSN
Agenus (AGEN) Registers Plan to Offer 165,000 Common Shares | AG - GuruFocus
Agenus: Q1 Earnings Snapshot - MySA
Agenus appoints oncology veteran Dr. Goldberg as CDO By Investing.com - Investing.com Canada
Agenus (AGEN) Sets Strategic Path with New Leadership and Transactions - GuruFocus
Agenus (AGEN) Sets Strategic Path with New Leadership and Transa - GuruFocus
Transcript : Agenus Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Agenus reports Q1 EPS ($1.03), consensus ($1.98) - TipRanks
Earnings call transcript: Agenus reports Q1 2025 net loss, stock rises premarket - Investing.com
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Agenus appoints oncology veteran Dr. Goldberg as CDO - Investing.com Australia
Agenus (AGEN) Reports Strong Q1 Revenue Surpassing Expectations - GuruFocus
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer | AGEN Stock News - GuruFocus
Agenus (AGEN) Reports Q1 Earnings, Beats EPS Estimates - GuruFocus
Agenus Inc (AGEN) Q1 2025 Earnings: EPS Beats Estimates at -$1.0 - GuruFocus
Agenus Reports Q1 2025 Financial Results and Key Business Updates | AGEN Stock News - GuruFocus
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):